Amylyx's Relyvrio pulls in $71M in revenue

Tyler Patchen

News Reporter

Amylyx’s ALS drug Relyvrio brought in $71.4 million in revenue in the first quarter of the year, far surpassing expectations for a CNS therapy approved …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amylyx's Relyvrio pulls in $71M in revenue

Tyler Patchen

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Amy­lyx's Re­lyvrio pulls in $71M in rev­enue

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Amylyx's Relyvrio pulls in $71M in revenue